AbbVie – Talk Bio

Spotlight On: Big Pharma’s Big Bets on In Vivo Cell Therapy

3 weeks ago talkbio0Tagged AbbVie, Acquisition, AstraZeneca, Autoimmune Diseases, CAR-T, Cell Therapy, gene therapy, Gilead, in vivo, Manufacturing, Myers Squibb, scalability

in vivo cell therapy; CAR-T; acquisition; autoimmune disease; gene therapy; manufacturing; scalability; Bristol Myers Squibb; Gilead; AbbVie; AstraZeneca

Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

3 weeks ago talkbio0Tagged AbbVie, Acquisition, Ambrx, Antibody-Drug Conjugates, Drug Development, GEN1107, Genmab, J&J, Johnson and Johnson, Neoplasms, ProfoundBio, PTK7, PTK7 protein, human

Genmab; ProfoundBio; antibody-drug conjugate (ADC); GEN1107; PTK7; Ambrx; Johnson & Johnson (J&J); oncology; drug development; biotech acquisition; AbbVie lawsuit

Zag Bio Launches with $80M to Teach the Immune System to Make Better Tregs

1 month ago talkbio0Tagged AbbVie, Autoimmune Diseases, Diabetes Mellitus, Insulin-Dependent, Funding, Immune Tolerance, Regeneron, Regulatory T-Lymphocytes, sanofi, Series A, thymus-targeted therapy, Tregs, Zag Bio

Zag Bio; Tregs; regulatory T cells; autoimmune diseases; thymus-targeted therapy; Series A funding; immune tolerance; Type 1 diabetes; AbbVie; Regeneron; Sanofi

Despite Government Shutdown, Companies Still Plan to Submit FDA Applications

2 months ago talkbio0Tagged AbbVie, amgen, Application procedure, biology (field), drug applications, funding lapse, Government, J&J, Myers Squibb, Pfizer, pharmaceutical delays, shutdown, United States Food and Drug Administration, user fees

FDA shutdown; new drug applications; biologic applications; user fees; pharmaceutical delays; government funding lapse; AbbVie; Amgen; Bristol Myers Squibb; J&J; Pfizer

AbbVie Extends Rinvoq Exclusivity to 2037, Delaying Generics in U.S.

3 months ago talkbio0Tagged AbbVie, exclusivity extension, Generic competition, Market, Patent Settlement, pharmaceutical litigation, Rinvoq, U.S., upadacitinib

AbbVie; Rinvoq; patent settlement; generic competition; exclusivity extension; upadacitinib; US market; pharmaceutical litigation

AbbVie Buys Gilgamesh’s Psychedelic Drug Bretisilocin for $1.2B

4 months ago talkbio0Tagged AbbVie, Acquisition, bretisilocin, Dosage Forms, Gilgamesh, GM-2505, Hallucinogens, mental health, Neuroscience discipline

AbbVie; Gilgamesh Pharmaceuticals; psychedelic drug; bretisilocin; GM-2505; major depressive disorder; acquisition; mental health; neuroscience; pharmaceutical deal

AbbVie’s Rinvoq Achieves Second Phase 3 Win in Alopecia Areata Trials

4 months ago talkbio0Tagged AbbVie, Alopecia, Eyebrow structure, Eyelash, hair regrowth, Rinvoq, safety profile, Salts, Score, upadacitinib

AbbVie; Rinvoq; upadacitinib; alopecia areata; Phase 3 clinical trial; hair regrowth; SALT score; eyebrows; eyelashes; safety profile

AbbVie’s Rinvoq Achieves Strong Phase 3 Results in Alopecia Areata, Clearing Key Efficacy Milestone

4 months ago talkbio0Tagged AbbVie, Alopecia, hair regrowth, Inhibitor, Janus kinase, Rinvoq, Salts, Score, upadacitinib

AbbVie; Rinvoq; Phase 3 trial; alopecia areata; hair regrowth; upadacitinib; SALT score; JAK inhibitor

AbbVie Invests $195 Million in New North Chicago API Manufacturing Site

4 months ago talkbio0Tagged AbbVie, alpha 1-antitrypsin, domestic production, expansion, Facility (object), Illinois (geographic location), Investments, Manufacturing, North Chicago, pharmaceutical manufacturing

AbbVie; North Chicago; API manufacturing; $195 million investment; facility expansion; pharmaceutical manufacturing; Illinois; domestic production

AbbVie and Genmab Move to Expand Use of T Cell Engager Epkinly Following Strong Phase III Results

4 months ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Approved, Epcoritamab, EPKINLY, expansion, Genmab, Labels (device), lenalidomide, Lymphoma, Follicular, Phase 3 Clinical Trials, rituximab, T-Cell engager, United States Food and Drug Administration

Epkinly; epcoritamab; AbbVie; Genmab; follicular lymphoma; T cell engager; bispecific antibody; Phase III trial; FDA approval; label expansion; Rituximab; Lenalidomide